Less than a year into his tenure as chief executive, Luke Miels has delivered one of the biggest moves in GSK's recent history, committing $10.6 billion (£7.9 billion) to strengthen the pharmaceutical giant's growing oncology business.
The British drugmaker announced it has agreed to acquire Nuvalent, a Boston-based biotechnology company focused on developing precision cancer therapies. The transaction, which values Nuvalent at $124 per share in cash, represents GSK's largest acquisition to date and signals a major expansion of its ambitions in cancer treatment.
The deal gives GSK access to a promising pipeline of targeted therapies, including two late-stage lung cancer drugs that could reach the market before the end of the year if approved by US regulators.
For Miels, who succeeded Emma Walmsley as CEO at the beginning of 2026, the acquisition marks the most significant strategic investment of his leadership so far and reinforces GSK's determination to become a leading force in oncology.
A Biotech Built Around Precision Medicine
Founded in 2017 by Harvard chemistry and chemical biology professor Matthew Shair, Nuvalent has quickly emerged as one of the most closely watched cancer-focused biotechnology companies in the United States.
The company specialises in developing targeted therapies designed to combat specific genetic mutations that drive tumour growth while reducing side effects often associated with traditional cancer treatments.
Nuvalent went public on the Nasdaq Stock Market in 2021 and has since attracted significant investor interest because of its focus on precision oncology.
Shair, who owns approximately 2.16% of the company, is expected to receive nearly $200 million from the acquisition based on current ownership data. The biotech's largest shareholder remains Deerfield Management, a New York-based healthcare investment firm.
Two Potential Blockbuster Drugs at the Centre of the Deal
The primary attraction for GSK lies in Nuvalent's advanced pipeline of lung cancer treatments.
Two experimental therapies—zidesamtinib and neladalkib—are currently under review by the US Food and Drug Administration (FDA), with regulatory decisions expected in September and November respectively.
Should the treatments receive approval, both could launch commercially later this year.
Industry analysts view the drugs as potential blockbuster products capable of generating several billion dollars in annual revenue. They are designed to treat forms of non-small cell lung cancer driven by specific genetic mutations, offering a more targeted approach than many existing therapies.
The affected patient population is relatively small but medically significant. The mutations primarily occur in non-smoking adults between the ages of 40 and 50 and disproportionately affect women. In the United States, fewer than 4,000 patients are diagnosed with these specific mutations.
GSK believes the drugs could offer a significant improvement in patient quality of life by delivering longer-lasting treatment responses while reducing some of the burdens associated with current therapies.
GSK's Largest Acquisition on Record
The Nuvalent purchase surpasses all previous acquisitions undertaken by GSK and ranks among the largest transactions in the company's modern history.
The last deal of comparable significance came in 2014 when GSK and Novartis completed a complex asset swap valued at approximately $21 billion. Under that arrangement, GSK acquired Novartis' vaccines division for $5.25 billion while selling its own oncology assets to the Swiss pharmaceutical group for $16 billion.
More than a decade later, GSK is effectively rebuilding and expanding its cancer business, this time through targeted acquisitions and internally developed medicines.
The latest transaction also follows a series of strategic deals completed under Miels' leadership.
Earlier this year, GSK acquired California-based biotechnology company RAPT Therapeutics for $2.2 billion. RAPT is developing treatments aimed at preventing severe food allergies, including allergies to nuts, milk, and eggs.
Miels Doubles Down on Oncology
While GSK's oncology ambitions were initially revived under former CEO Emma Walmsley, Miels appears prepared to accelerate that strategy.
Investors had expected the company to continue pursuing smaller acquisitions, making the scale of the Nuvalent deal something of a surprise.
Despite the size of the investment, Miels insists the acquisition aligns with GSK's long-term approach.
"We're following a brick-by-brick approach," he said.
"The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer."
According to Miels, discussions with Nuvalent stretched over more than a year before culminating in the acquisition.
"I really became convinced that this was a deal that we needed to do," he said, describing Nuvalent's researchers as an "impressive group of people."
Addressing an Unmet Need for Patients
One of the factors that convinced GSK to proceed was the potential to improve treatment experiences for patients currently living with these forms of lung cancer.
Miels highlighted the limitations of existing therapies, noting that many patients remain on treatment for seven to eight years while coping with challenging side effects.
"These are relatively young people. They've got kids, they [lead] active lives," he said. "Clearly there's a gap for a much better-tolerated product."
The focus on tolerability reflects a broader shift in cancer treatment, where drugmakers are increasingly seeking not only to extend survival but also to improve patients' quality of life during treatment.
Looking Beyond Lung Cancer
The acquisition also gives GSK access to a broader oncology platform that could support future growth.
Among the assets included in the transaction is Ris-Rez, a late-stage development programme that the company believes could eventually be used across multiple cancer types.
Executives expect the product to contribute to GSK's long-term ambition of generating more than £40 billion in annual revenue by 2031.
That target remains ambitious and has drawn some scepticism from industry analysts, particularly as competition intensifies across the global pharmaceutical market.
Notably, GSK's current revenue projections do not yet include potential contributions from the Nuvalent acquisition, suggesting management sees additional upside if the deal performs as expected.
Market Reacts to the Announcement
Investors responded positively to the news for Nuvalent, whose shares surged 38% in pre-market trading to approximately $122 following the announcement.
GSK shares, however, slipped around 3% as investors weighed the financial implications of the multibillion-dollar acquisition and assessed the risks associated with integrating a biotechnology company whose key products are still awaiting regulatory approval.
Nevertheless, the transaction underscores GSK's growing confidence in oncology as a central pillar of its future growth strategy.
For Miels, the acquisition represents more than just a major purchase. It is an early statement of intent—one that signals GSK's willingness to deploy significant capital in pursuit of breakthrough medicines and a stronger position in one of the pharmaceutical industry's most competitive and lucrative markets.